Fate Therapeutics, Inc. earnings per share and revenue
On Nov 13, 2025, FATE reported earnings of -0.27 USD per share (EPS) for Q3 25, beating the estimate of -0.29 USD, resulting in a 9.06% surprise. Revenue reached 1.74 million, compared to an expected 1.57 million, with a 11.20% difference. The market reacted with a -4.59% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 1.21 million USD, implying an increase of 0.00% EPS, and decrease of -30.52% in Revenue from the last quarter.
FAQ
What were Fate Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Fate Therapeutics, Inc. reported EPS of -$0.27, beating estimates by 9.06%, and revenue of $1.74M, 11.2% above expectations.
How did the market react to Fate Therapeutics, Inc.'s Q3 2025 earnings?
The stock price moved down -4.59%, changed from $1.04 before the earnings release to $0.99 the day after.
When is Fate Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Mar 03, 2026.
What are the forecasts for Fate Therapeutics, Inc.'s next earnings report?
Based on 15
analysts, Fate Therapeutics, Inc. is expected to report EPS of -$0.27 and revenue of $1.21M for Q4 2025.